Search our Innovation Portfolio

Respiratory tract infections (RTIs) are the most common reason for primary care consultations, accounting for 17 million consultations in the European Union. Antibiotics are commonly prescribed in primary care for RTIs for both adults and children even though in most cases they are viral infections. Our new product will improve patient outcomes by enabling healthcare practitioners to distinguish between viral or bacterial infections by measuring exhaled breath volatile organic compound (VOC) biomarkers. It has the potential to change current practice by informing the GP to prescribe antibiotics for people with symptoms of respiratory tract infections during a primary care consultation.

Exhale-Dx represents an innovative diagnostic breath test platform adept at predicting asthma attacks and effectively monitoring asthma control. By harnessing artificial intelligence Exhale-Dx meticulously analyzes breath samples for biomarkers, offering a non-invasive and early-detection solution for various respiratory conditions. Our ongoing project focuses on adapting Exhale-Dx for pediatric use, aiming to expand its global reach. This device holds the potential to identify asthma exacerbations before they escalate. Particularly in underserved communities, where access to healthcare may be limited, early detection can mitigate the need for emergency room visits and hospitalisations, thus reducing health disparities through timely intervention.